Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

HUTCHMED signs licensing deal with GSK for experimental solid tumour drug | PharmaVoice

ET Pharma

HUTCHMED signs licensing deal with GSK for experimental solid tumour drug

Sep 4, 2026, 2:47 AM

Read Full Article →

Translate article text

Choose a language and wait for the translated text.

Clinical development for HMPL-A830 will focus initially on "colorectal, pancreatic and lung cancer indications", HUTCHMED said in a filing to the Hong Kong stock exchange.